INS and metabolic dysfunction-associated steatotic liver disease: In nondiabetic patients with NAFLD, MET administration for 12 months ameliorated liver fibrosis, necrosis, inflammation, and lipid deposition, normalized the serum liver profile, and enhanced insulin sensitivity [63].